|Articles|September 17, 2020
FDA May Delay Approval of Drugs Where Necessary Inspection is Not Feasible
FDA to resume “prioritized domestic inspections” for certain regulated products put on hold by COVID-19.
Advertisement
FDA announced recently that it planned to resume “prioritized domestic inspections” for certain regulated products that had been put on hold by COVID-19 since March. The agency also would continue to conduct “mission critical” inspections , utilizing methods to ensure the safety of all involved personnel. But it was unclear to biopharma companies from the July 10 press release which products and situations would warrant on-site visits and how the agency would respond where the pandemic made an inspection unsafe or unfeasible.
Now a new guidance from FDA provides answers to such questions about when the agency will seek to visit a site and how it will respond when a needed inspection cannot be conducted safely. FDA explains that it may delay approval of new products in situations where travel restrictions and other concerns block a pre-approval inspection that the agency considers necessary.
Breakthrough therapies and regenerative medicine advanced therapies may gain approval even without a desired inspection. This policy also applies to other mission critical therapies used to diagnose, treat, or prevent a serious disease where no treatment alternative is available.
However, if an application involves a less critical medicine, and FDA has concerns about the adequacy of the facility but cannot conduct a site visit before the application’s “action date,” then FDA will issue a complete response letter that explains the reasons for delaying approval.
The agency will try to avoid such situations by utilizing other methods to access needed information on a manufacturing operation without an actual site visit. FDA will review earlier inspection reports, request records and information from the applicant and from the facility, and seek to obtain inspection reports from other trusted foreign regulatory partners. And for drugs made overseas where inspections continue to remain on hold, the agency will review product quality through sampling and testing at border control sites.
Similar assessments will apply to Bioresearch Monitoring (BIMO) surveillance of research sites, conducted to ensure that investigators follow policies to protect research subjects and to ensure the accuracy of clinical trial data. Here, FDA will continue to follow risk-based approaches that consider the nature of the application and site-specific factors.
The new guidance also provides flexibility for manufacturers looking to make changes in a facility or production process for an approved product affected by supply chain disruptions due to the pandemic. FDA will expedite such requests for drugs and biologics used in treating COVID-19 patients and for critical products in shortage situations. This will involve weighing the impact of post-approval changes and a firm’s efforts to mitigate the risk to product quality associated with a change. For critical products, FDA may permit a manufacturer to use a lower reporting category to facilitate the change and avoid C review and inspection of the changes.
Jill Wechsler is Applied Clinical Trials' Washington Editor
Articles in this issue
almost 5 years ago
News Notesalmost 5 years ago
Innovative Clinical Trial Designs Emerge from Pandemicalmost 5 years ago
Applying Pre-Pandemic Benchmarks to Assess Future Speed Strategiesalmost 5 years ago
Silver Linings of Post-Pandemic Trial Disruptionalmost 5 years ago
Debate Accelerates Over Who Gets COVID Vaccine Firstalmost 5 years ago
FDA’s ‘Gold Standard’ Critical for Biopharma R&Dalmost 5 years ago
Decentralized Trials: Opening New Opportunities in Clinical Researchalmost 5 years ago
The Rise of FSP Outsourcing in Drug Developmentalmost 5 years ago
Trial Innovation Beyond the COVID-19 Pandemicalmost 5 years ago
Small Biopharma and CROs: Seeking Stronger Synergiesalmost 5 years ago
Applied Clinical Trials, September 2020 Issue (PDF)almost 5 years ago
EU Makes More Vaccine Deals as Questions Mount Over Termsalmost 5 years ago
Integration of Point-of-Care Devices in Clinical TrialsNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- What Resilient Trial Design Means for Clinical Teams
September 2nd 2025
- Why Clinical Trial Innovations Take Years to Gain Adoption
August 29th 2025
- How Research Sites Balance Funding Cuts and Efficiency Pressures
August 26th 2025
- FDA Expands Transparency With Daily Adverse Event Reporting
August 25th 2025
- DEI & Clinical Trials: Navigating Policy Shifts
August 22nd 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
2
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
3
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
4
AstraZeneca’s Tagrisso Shows Landmark Overall Survival Benefit in Non-Small Cell Lung Cancer
5